The CRISPR/Cas9 system targeting EGFR exon 17 abrogates NF-κB activation via epigenetic modulation of UBXN1 in EGFRwt/vIII glioma cells.
Huang K, Yang C, Wang QX, Li YS, Fang C, Tan YL, Wei JW, Wang YF, Li X, Zhou JH, Zhou BC, Yi KK, Zhang KL, Li J, Kang CS.
Huang K, et al. Among authors: li j, li x, li ys.
Cancer Lett. 2017 Mar 1;388:269-280. doi: 10.1016/j.canlet.2016.12.011. Epub 2016 Dec 18.
Cancer Lett. 2017.
PMID: 27998759